Chimeric Therapeutics (ASX:CHM) reports successful 28-day follow up phase 1 trial

Company News

by Melissa Darmawan

Biotech company Chimeric Therapeutics (ASX:CHM) reports another successful update on their phase 1 clinical trial in the City of Hope hospital in California, a cancer research and treatment centre in the USA.

Patients from the first cohort have moved beyond the 28-day follow up period, without experiencing any side effects from their dose. This comes after their completion of the trial to evaluate the safety and maximum dose of chlorotoxin CAR T in patients with a brain tumour last month.

The company focuses on chlorotoxin CAR T which is a cell therapy compound to help patients with cancer. This milestone will enable them to advance in the next step of the trial to advance to the second dosing level.

Shares in Chimeric (ASX:CHM) last traded 1.69 per cent higher at 30 cents.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.